Hematology/Oncology

Top Story

Patients may have unrealistic expectations of phase 1 oncology trials

September 26, 2016

Nearly half of patients with cancer expected that their tumors would shrink while on a phase 1 study, although the typical response rate observed in early-phase trials ranges from 4% to 20%, according to results of a single-center, prospective, quantitative study.

Still, a majority of patients were willing to participate in phase 1 trials after they consulted the pros and cons with their physicians, results showed.

Meeting News Coverage

Financial burdens more common in black cancer survivors

September 26, 2016
Black cancer survivors appeared more likely than white survivors to face lasting debt and limit their medical care due to cost concerns, according to study results…
Meeting News Coverage

Androgen receptor expression uncommon in black women with triple-negative breast cancer

September 26, 2016
Black women with triple-negative breast cancer appeared more likely to lack the androgen receptor protein compared with white women, according to study data presented at…

Fox Chase Cancer Center announces faculty appointments

September 25, 2016
Fox Chase Cancer Center announced several faculty appointments. Allison Aggon , DO, has joined the department of surgical oncology with a focus…
Commentary

Navigating the National Health System: A personal experience

HemOnc Today, September 25, 2016
Jai N. Patel, PharmD
An experience abroad had me contemplating the state of our health system in the United States and the implications of nationalized health care. It is evident that no…
More News Headlines »
CME

The Patient with Multiple Ecchymoses

No commercial support for this activity.

Glanzmann’s thrombasthenia is a rare, inherited bleeding disorder that results from a mutation in αIIbß3, an integrin…
More »
Video
Meeting News Coverage

VIDEO: Combination therapy with PD-L1, PARP inhibitors appears effective in patients with ovarian, breast cancer

September 8, 2016
More »
Featured
At Issue: Breast Cancer Resource Center

At Issue: Breast Cancer Resource Center

CME

The Patient with Castration-resistant Prostate Cancer

No commercial support for this activity.

Castration-resistant prostate cancer (CRPC) is a heterogeneous condition that encompasses a continuum of disease…
More »
Current Issues
View the Current Issue
HemOnc Today
morganatic-roan
morganatic-roan